Skip to main content
Deciphera
Deciphera

Main Utility

  • Patients & Caregivers
  • Healthcare Professionals
  • Clinical Studies
  • Presentations & Publications
  • Investors & News
twitter linkedin

Main navigation

  • Discovery Platform
  • Pipeline
    • Ripretinib
    • Vimseltinib
    • DCC-3116
    • Preclinical Pipeline
    • Expanded Access
  • Our Medicine
    • QINLOCK® (ripretinib)
  • Who We Are
    • Management
    • Board of Directors
  • Join Us
    • Open Positions

Main navigation

  • Discovery Platform
  • Pipeline
    • Ripretinib
    • Vimseltinib
    • DCC-3116
    • Preclinical Pipeline
    • Expanded Access
  • Our Medicine
    • QINLOCK® (ripretinib)
  • Who We Are
    • Management
    • Board of Directors
  • Join Us
    • Open Positions

Main Utility

  • Patients & Caregivers
  • Healthcare Professionals
  • Clinical Studies
  • Presentations & Publications
  • Investors & News
twitter linkedin

Board of Directors

Ron Squarer

Patricia L. Allen

Edward J. Benz, Jr., M.D.

Frank S. Friedman

James A. Bristol, Ph.D.

Steven L. Hoerter

Susan L. Kelley, M.D.

John R. Martin

Dennis L. Walsh

Deciphera
twitter linkedin
contact us

Main navigation

  • Discovery Platform
  • Pipeline
    • Ripretinib
    • Vimseltinib
    • DCC-3116
    • Preclinical Pipeline
    • Expanded Access
  • Our Medicine
    • QINLOCK® (ripretinib)
  • Who We Are
    • Management
    • Board of Directors
  • Join Us
    • Open Positions

Footer Utility

  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Recruiting Privacy Policy
  • Web Accessibility Statement

© 2023 Deciphera Pharmaceuticals, Inc. QINLOCK and the QINLOCK logo are registered trademarks of Deciphera Pharmaceuticals, LLC. Deciphera and the Deciphera logo are trademarks of Deciphera Pharmaceuticals, LLC.